Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
06 2020
Historique:
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 29 7 2021
Statut: ppublish

Résumé

Utilization of clinical technology and mobile health (mHealth) is expanding globally. It is important to reflect on how their usage and application could translate in low- and middle-income country (LMIC) settings. With the exponential growth and advancements of mobile and wireless technologies, LMICs are prime to adapt such technologies to potentially democratize and create solutions to health-related challenges. The role of these technologies in oncology clinical trials continues to expand. The lure of mHealth promises disruptive technology that may change the way clinical trials are designed and conducted in many settings. Its applicability in the African context is currently under consideration. Although potentially of expanding benefit, the role of these technologies requires careful and nuanced evaluation of the context in which they might be applied to harness their full potential, while mitigating possible harms or preventing further deepening of disparities within populations. Moreover, technology and digital innovations are no substitute for poor referral pathways and dysfunctional health systems and can only complement or enhance definite strategies aimed at strengthening these health systems.

Identifiants

pubmed: 32614724
doi: 10.1200/JGO.19.00191
pmc: PMC7392770
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

948-953

Subventions

Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States

Références

BMC Womens Health. 2019 Jan 7;19(1):2
pubmed: 30616579
Indian J Pharmacol. 2018 May-Jun;50(3):105-107
pubmed: 30166746
N Engl J Med. 2017 Mar 2;376(9):856-867
pubmed: 28249147
Glob J Health Sci. 2016 Jan 21;8(9):54429
pubmed: 27157176
Methods Inf Med. 2017 Aug 08;56(7):e105-e122
pubmed: 28925418
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
Telemed J E Health. 2012 Jan-Feb;18(1):11-3
pubmed: 22171597
PLoS One. 2013;8(1):e54066
pubmed: 23349786
BMJ Glob Health. 2019 Apr 11;4(2):e001395
pubmed: 31139457
BMJ. 2016 Mar 17;352:i1174
pubmed: 26988021
BMC Public Health. 2014 Feb 21;14:188
pubmed: 24555733
Glob Health Action. 2019;12(1):1559268
pubmed: 31154994

Auteurs

Miriam Mutebi (M)

Aga Khan University, Nairobi, Kenya.

Rohini Bhatia (R)

Sinai Hospital of Baltimore, Baltimore, MD.

Omolola Salako (O)

Lagos University Teaching Hospital, Lagos, Nigeria.

Fidel Rubagumya (F)

Rwanda Military Hospital, University of Global Health Equity, Kigali, Rwanda.

Surbhi Grover (S)

University of Pennsylvania, Philadelphia, PA.

Nazik Hammad (N)

Queen's University Cancer Center of Southeastern Ontario, Kingston Health Science Center, Kingston, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH